{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:18:42Z","timestamp":1784791122917,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00108-026-02145-x","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:37:09Z","timestamp":1783085829000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressionshemmung bei chronischer Nierenkrankheit","Progression inhibition in chronic kidney disease"],"prefix":"10.1007","volume":"67","author":[{"given":"Julia","family":"Weinmann-Menke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"5","key":"2145_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","volume":"178","author":"M Madero","year":"2025","unstructured":"Madero\u00a0M, Levin\u00a0A, Ahmed\u00a0SB, Carrero\u00a0JJ, Foster\u00a0B, Francis\u00a0A et\u00a0al (2025) Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline. Ann Intern Med 178(5):705\u2013713","journal-title":"Ann Intern Med"},{"issue":"4","key":"2145_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin\u00a0A, Ahmed\u00a0SB, Carrero\u00a0JJ, Foster\u00a0B, Francis\u00a0A, Hall\u00a0RK et\u00a0al (2024) Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int 105(4):684\u2013701","journal-title":"Kidney Int"},{"issue":"4S","key":"2145_CR3","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4S):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"10523","key":"2145_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0140-6736(25)01942-7","volume":"407","author":"WG Herrington","year":"2026","unstructured":"Herrington\u00a0WG, Judge\u00a0PK, Grams\u00a0ME, Wanner\u00a0C (2026) Chronic kidney disease. Lancet 407(10523):90\u2013104","journal-title":"Lancet"},{"issue":"4","key":"2145_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.ajkd.2022.09.012","volume":"81","author":"YJ Um","year":"2023","unstructured":"Um\u00a0YJ, Chang\u00a0Y, Kim\u00a0Y, Kwon\u00a0MJ, Jung\u00a0HS, Lee\u00a0KB et\u00a0al (2023) Risk of CKD Following Detection of Microscopic Hematuria: A\u00a0Retrospective Cohort Study. Am J Kidney Dis 81(4):425\u2013433","journal-title":"Am J Kidney Dis"},{"key":"2145_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep15242","volume":"5","author":"H You-Hsien Lin","year":"2015","unstructured":"You-Hsien Lin\u00a0H, Yen\u00a0CY, Lim\u00a0LM, Hwang\u00a0DY, Tsai\u00a0JC, Hwang\u00a0SJ et\u00a0al (2015) Microscopic Haematuria and Clinical Outcomes in Patients With Stage 3\u20115 Nondiabetic Chronic Kidney Disease. Sci Rep 5:15242","journal-title":"Sci Rep"},{"issue":"1","key":"2145_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0951-0","volume":"19","author":"PF Orlandi","year":"2018","unstructured":"Orlandi\u00a0PF, Fujii\u00a0N, Roy\u00a0J, Chen\u00a0HY, Lee Hamm\u00a0L, Sondheimer\u00a0JH et\u00a0al (2018) Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. BMC Nephrol 19(1):150","journal-title":"BMC Nephrol"},{"issue":"1","key":"2145_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.kint.2023.09.012","volume":"105","author":"S Bhandari","year":"2024","unstructured":"Bhandari\u00a0S, Mehta\u00a0S, Khawaja\u00a0A, Cleland\u00a0JGF, Ives\u00a0N, Cockwell\u00a0P (2024) Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. Kidney Int 105(1):200\u2013208","journal-title":"Kidney Int"},{"key":"2145_CR9","doi-asserted-by":"publisher","unstructured":"Ku E, Inker LA, Tighiouart H, et al. (2024) Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant\u2013Level Meta-Analysis of Clinical Trials. Ann Intern Med. 177(7):953\u2013963. https:\/\/doi.org\/10.7326\/M23-3236","DOI":"10.7326\/M23-3236"},{"issue":"10365","key":"2145_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies G","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT (2022) Impact of diabetes on the effects of sodium glucose co-transporter\u20112 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801","journal-title":"Lancet"},{"issue":"2","key":"2145_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The E\u2011KCG, Herrington\u00a0WG, Staplin\u00a0N, Wanner\u00a0C, Green\u00a0JB, Hauske\u00a0SJ et\u00a0al (2023) Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"3","key":"2145_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen\u00a0BL, Fletcher\u00a0RA, Anker\u00a0SD, Bhatt\u00a0DL, Butler\u00a0J, Cherney\u00a0DZI et\u00a0al (2026) SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA 335(3):233\u2013244","journal-title":"JAMA"},{"issue":"1","key":"2145_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7326\/M22-2115","volume":"176","author":"M Schechter","year":"2023","unstructured":"Schechter\u00a0M, Jongs\u00a0N, Chertow\u00a0GM, Mosenzon\u00a0O, McMurray\u00a0JJV, Correa-Rotter\u00a0R et\u00a0al (2023) Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. Ann Intern Med 176(1):59\u201366","journal-title":"Ann Intern Med"},{"issue":"12","key":"2145_CR14","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","volume":"34","author":"RA Fletcher","year":"2023","unstructured":"Fletcher\u00a0RA, Jongs\u00a0N, Chertow\u00a0GM, McMurray\u00a0JJV, Arnott\u00a0C, Jardine\u00a0MJ et\u00a0al (2023) Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. J\u00a0Am Soc Nephrol 34(12):1965\u20131975","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2145_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","volume":"103","author":"GL Bakris","year":"2023","unstructured":"Bakris\u00a0GL, Ruilope\u00a0LM, Anker\u00a0SD, Filippatos\u00a0G, Pitt\u00a0B, Rossing\u00a0P et\u00a0al (2023) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196\u2013206","journal-title":"Kidney Int"},{"issue":"6","key":"2145_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, Filippatos\u00a0G, Pitt\u00a0B, Anker\u00a0SD, Rossing\u00a0P, Joseph\u00a0A et\u00a0al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484","journal-title":"Eur Heart J"},{"issue":"23","key":"2145_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD, Pitt\u00a0B, Ruilope\u00a0LM, Rossing\u00a0P et\u00a0al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"2145_CR18","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"American Diabetes Association Professional Practice Committee for D","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for D (2026) 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care 49(Supplement_1):S246\u2013S260","journal-title":"Diabetes Care"},{"key":"2145_CR19","doi-asserted-by":"publisher","unstructured":"Heerspink\u00a0HJL, Neuen\u00a0BL, Agarwal\u00a0R, Cherney\u00a0DZI, Lam\u00a0CSP, Tuttle\u00a0KR, Wanner\u00a0C et\u00a0al (2026) Finerenone in Persons with Chronic Kidney Disease without Diabetes    https:\/\/doi.org\/10.1056\/NEJMoa2604625","DOI":"10.1056\/NEJMoa2604625"},{"issue":"24","key":"2145_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, Brown-Frandsen\u00a0K, Colhoun\u00a0HM, Deanfield\u00a0J, Emerson\u00a0SS, Esbjerg\u00a0S et\u00a0al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"2","key":"2145_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, Tuttle\u00a0KR, Rossing\u00a0P, Mahaffey\u00a0KW, Mann\u00a0JFE, Bakris\u00a0G et\u00a0al (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 391(2):109\u2013121","journal-title":"N Engl J Med"},{"issue":"10416","key":"2145_CR22","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink\u00a0HJL, Kiyosue\u00a0A, Wheeler\u00a0DC, Lin\u00a0M, Wijkmark\u00a0E, Carlson\u00a0G et\u00a0al (2023) Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402(10416):2004\u20132017","journal-title":"Lancet"},{"issue":"10424","key":"2145_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle\u00a0KR, Hauske\u00a0SJ, Canziani\u00a0ME, Caramori\u00a0ML, Cherney\u00a0D, Cronin\u00a0L et\u00a0al (2024) Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403(10424):379\u2013390","journal-title":"Lancet"},{"issue":"6","key":"2145_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal\u00a0R, Green\u00a0JB, Heerspink\u00a0HJL, Mann\u00a0JFE, McGill\u00a0JB, Mottl\u00a0AK et\u00a0al (2025) Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med 393(6):533\u2013543","journal-title":"N Engl J Med"},{"key":"2145_CR25","doi-asserted-by":"publisher","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffey\u00a0KW, de Zeeuw\u00a0D, Fulcher\u00a0G, Erondu\u00a0N, Shaw\u00a0W, Law\u00a0G, Desai\u00a0M, Matthews\u00a0DR, (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes for the CANVAS Program Collaborative Group. N Engl J Med 377:644-657 https:\/\/doi.org\/10.1056\/NEJMoa1611925","DOI":"10.1056\/NEJMoa1611925"},{"key":"2145_CR26","doi-asserted-by":"publisher","unstructured":"Fernandez-Fernandezn\u00a0B, Fernandez-Pradon\u00a0R, G\u00f3rrizn\u00a0JL, Martinez-Castelaon\u00a0A, Navarro-Gonz\u00e1lezn\u00a0JF, Porrinin\u00a0E, Solern\u00a0MJ, Ortizn\u00a0A. (2019) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J. 31;12(3):313-321. https:\/\/doi.org\/10.1093\/ckj\/sfz070. PMID: 31198532; PMCID: PMC6543971.","DOI":"10.1093\/ckj\/sfz070"},{"issue":"22","key":"2145_CR27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen\u00a0BL, Fletcher\u00a0RA, Heath\u00a0L, Perkovic\u00a0A, Vaduganathan\u00a0M, Badve\u00a0SV et\u00a0al (2024) Cardiovascular, Kidney, and Safety Outcomes With GLP\u20111 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation 150(22):1781\u20131790","journal-title":"Circulation"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02145-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:53:25Z","timestamp":1784789605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02145-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Weinmann-Menke erhielt Honorare von AstraZeneca, Boehringer-Ingelheim, Lilly, GSK, Otsuka, Novartis, Sobi und CSL-Vifor. J.\u00a0Galle gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}